Has Amber Downes received payments from drug or device companies?

Yes. Drug and device makers reported $1,244 in general payments to Amber Downes across 72 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Amber Downes did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Amber Downes come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Amber Downes

Physician Assistant · Benbrook, TXNPI 1801811419

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,084 and has fallen 99.4% since, to $7 in 2024.

$1,244in general payments, 2019–2025

Across 72 payments — averaging $17.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boehringer Ingelheim$211
AstraZeneca$153
AbbVie$134
Novo Nordisk$133
GSK$73
Pfizer$64
plus $478 from 17 others

What the payments were for

Food & beverage$1,244100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boehringer Ingelheim	8	$211
AstraZeneca	3	$153
AbbVie	9	$134
Novo Nordisk	10	$133
GSK	5	$73
Pfizer	4	$64
Lilly USA, LLC	4	$60
Genentech USA, Inc.	4	$49
Abbott	2	$48
Biohaven Pharmaceuticals, Inc.	2	$38
Takeda Pharmaceuticals U.S.A., Inc.	2	$30
Johnson & Johnson	2	$29
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$28
Novartis	2	$27
Organon	5	$24
Dexcom, Inc.	1	$22
Nestle Healthcare Nutrition Inc.	1	$22
Mylan Specialty L.p.	1	$21
Seqirus USA Inc	1	$20
Sanofi-aventis U.S. LLC	1	$17
Otsuka America Pharmaceutical, Inc.	1	$16
Amarin Pharma, Inc.	1	$15
Astellas Pharma US Inc	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

FARXIGA$124

How this compares

$1,244 in reported general payments places this provider in the 65th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas →

Other physician assistant in Benbrook

Cynthia TrickettDallas$1.3M
Kristine KuceraMelissa$797K
Selina SantosAustin$543K
Matthew BrunoMcKinney$538K
Brooke HodnickSouthlake$479K
Holly GloverArlington$418K
Kirk GautierAthens$416K
Jaime RomanPlano$338K
Michael WhiteDallas$276K
Heidi JeffreysLubbock$259K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →